Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: A propensity analysis

Marzia Lazzari, Maria Teresa Greco, Claudio Marcassa, Simona Finocchi, Clarissa Caldarulo, Oscar Corli

Research output: Contribution to journalArticlepeer-review

Abstract

Background: World Health Organization step III opioids are required to relieve moderate-to-severe cancer pain; constipation is one of the most frequent opioid-induced side effects. A fixed combination, prolonged-release oxycodone/naloxone (OXN), was developed with the aim of reducing opioid-related gastrointestinal side effects. The objective of this study was to compare the efficacy and safety of prolonged-release oxycodone (OXY) alone to OXN in opioid-naïve cancer patients with moderate-to-severe pain. Methods: Propensity analysis was utilized in this observational study, which evaluated the efficacy, safety, and quality of life. Results: Out of the 210 patients recruited, 146 were matched using propensity scores and included in the comparative analysis. In both groups, pain intensity decreased by ≈3 points after 60days, indicating comparable analgesic efficacy. Responder rates were similar between groups. Analgesia was achieved and maintained with similarly low and stable dosages over time (12.0–20.4mg/d for OXY and 11.5–22.0mg/d for OXN). Bowel Function Index (BFI) and laxative use per week improved from baseline at 30days and 60days in OXN recipients (-16,P

Original languageEnglish
Pages (from-to)5863-5872
Number of pages10
JournalDrug Design, Development and Therapy
Volume9
DOIs
Publication statusPublished - Nov 2 2015

Keywords

  • Analgesia
  • Cancer pain
  • Naloxone
  • Oxycodone
  • Propensity analysis

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: A propensity analysis'. Together they form a unique fingerprint.

Cite this